checkedPsychopharmacology and Psychiatry Updates2026-11-13last verified 2026-11-13

did 38% of programs treat a past liver transplant as a reason not to start methadone?

verdict: misattributed
a real number attached to the wrong thing
“There's a 2017 survey, which is Fleming et al 2017, 38% of programs considered a relative contraindication if somebody had had liver transplant for starting them on methadone.”

a guest, Dr. Kevin A. Severino, lecturer on addiction psychopharmacology said on Psychopharmacology and Psychiatry Updates, 2026-11-13, at 06:17. hear it in context → the speaker cited: Fleming et al 2017 survey.

the episode: Liver Disease: Buprenorphine, Methadone, and Smoking Cessation Agents (at 06:17). we link the show's own page; we do not re-host audio.

first, the part that holds

the survey is real, it was published in 2017, and its lead author is the one the speaker named. the 38% is also real: 37.7% of responding programs called opioid substitution therapy a relative contraindication.

what we found when we went and looked

we read the 2017 survey in clinical transplantation (pmid 28941292, full text on pmc). it went to us liver transplant centers, not to opioid treatment programs, and 61 of 114 centers answered. 37.7% of those centers said opioid substitution therapy (methadone or buprenorphine, counted together) was a relative contraindication to liver transplant, and one center (1.6%) called it an absolute contraindication. so the number is right but the direction is reversed. the survey asked whether being on methadone or buprenorphine counts against getting a transplant. it did not ask whether having had a transplant counts against starting methadone, and nothing in the paper measures that.

assertion by assertion

assertionverdictwhat the record says
a 2017 survey by fleming et al. exists on this topicconfirmedfleming and colleagues, 'opioid and opioid substitution therapy in liver transplant candidates: a survey of center policies and practices,' clinical transplantation 2017;31(12), doi 10.1111/ctr.13119. the survey ran from october 2016 to february 2017. [1][2]
38% of programs considered it a relative contraindicationconfirmedthe paper reports 37.7%, which rounds to 38%. the denominator is the 61 of 114 centers that responded (53.5%), covering 49.2% of 2016 liver transplant volume. it is not all programs. [1][2]
the programs surveyed were opioid treatment programsmisattributedthe survey was sent to all active us liver transplant centers listed in the unos database. most respondents were transplant hepatologists (62.3%) or transplant pharmacists (31.1%). no opioid treatment programs were surveyed. [1][2]
prior liver transplant was treated as a relative contraindication to starting methadonemisattributedthe direction is reversed. 37.7% of centers called opioid substitution therapy 'a relative or absolute contraindication to transplant' for transplant candidates (the relative share alone is 37.7%, the absolute share 1.6%). the paper has no data on starting methadone after a transplant. [1][2]
the 38% applies to methadone specificallyoverstatedthe survey grouped methadone and buprenorphine together as opioid substitution therapy and did not break them out. the only methadone-specific numbers in the paper come from a 2001 survey it cites, in which 32% of programs required methadone to be stopped before transplant. [1]

both directions

for the speaker: the citation, the year and the number are all correct, and the figure is about methadone-type treatment and liver transplant. it is easy to garble on air: the original statement is 'about 38% of liver transplant centers treat being on methadone or buprenorphine as a relative contraindication to transplant.' the broader point behind the quote, that methadone and liver transplant often collide in policy, is supported. among the 24 centers that saw opioid substitution therapy as a contraindication, 33.3% required doses below a threshold, 16.7% required weaning off for a period, and 50% required co-management with psychiatry, addiction medicine or pain management. a 2024 review in liver transplantation repeats the 38% figure the same way.

against: the people surveyed and the direction of the barrier are both wrong in the claim as stated. this was a survey of transplant centers deciding whether to list people already on methadone or buprenorphine. it says nothing about opioid treatment programs refusing to start methadone in someone who has had a transplant. the 38% also covers methadone and buprenorphine together, and it comes from about half of us centers, not all of them. only one center called the treatment an absolute contraindication, and the authors' main finding was that most centers did not treat opioid substitution therapy as an absolute bar to transplant.

what this cannot say

a 53.5% response rate may not reflect centers that did not answer. respondents gave their center's policy themselves, and 73.8% to 78.7% of programs had no written policy, so 'relative contraindication' was left undefined and judged case by case. the survey is from 2016-2017, so current practice may be different. we worked from the pmc full text and a 2024 review that cites it. we could not load the publisher page or the pubmed page in this session, and we did not see the survey instrument itself. we checked only the quote as transcribed, and a slip of the tongue on air can't be ruled out. we found no survey of opioid treatment programs on methadone after transplant, so the reversed version of the claim is unverifiable, not disproven.

the medication pages behind this check

sources, each one fetched and read

  1. Fleming JN et al. Opioid and opioid substitution therapy in liver transplant candidates: a survey of center policies and practices. Clinical Transplantation 2017;31(12). doi:10.1111/ctr.13119; PMID 28941292; PMC6392463 What we read there: surveyed all active us liver transplant centers (unos database); 61/114 (53.5%) responded. 'Only two programs considered chronic opioid (1 [1.6%]) or OST use (1 [1.6%]) absolute contraindications to transplant'; for opioid substitution therapy, '37.7% and 1.6% considered it to be a relative or absolute contraindication, respectively.' opioid substitution therapy is defined as including methadone and buprenorphine. Fetched 2026-11-13 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC6392463
  2. Opioid Use and Risks in Liver Transplant Candidates and Recipients. Liver Transplantation, 2024 (online April 29, 2024) What we read there: citing fleming et al.: 'In a 2016 survey of 61 LT centers', chronic opioid use was a relative contraindication to transplant for 64% of respondents, medications for opioid use disorder were a relative contraindication for 38%, and 17% required tapering off before transplant. Fetched 2026-11-13 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC11518881/

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam